GE Healthcare axquires U-Systems Inc., developer of the Automated Breast Ultrasound, a system used as a supplement to mammography for asymptomatic women with dense breasts and no prior interventions.
GE Healthcare announced last week the acquisition of U-Systems Inc., developer of a breakthrough ultrasound system approved for breast cancer screening.
U-Systems’ somo•v® Automated Breast Ultrasound (ABUS) was approved by the FDA in September as an adjunct to mammography for asymptomatic women with dense breasts and no prior breast interventions. The companies did not disclose the financial terms of the acquisition.
“The combination of U-Systems, Inc. and GE Healthcare uniquely positions GE to offer U.S. healthcare providers and their patients the most comprehensive portfolio of breast care innovations on the market - from screening to diagnosis to monitoring,” Tom Gentile, president and CEO of GE Healthcare Systems, said in a statement.
Studies have shown that women with dense breast tissue are at a greater risk of breast cancer compared with those with little or no dense tissue.
"The worldwide resources of GE Healthcare will allow us to expand and accelerate our efforts to commercialize the recently FDA-Approved somo•v® ABUS,” Ron Ho, U-Systems president and CEO, said in a statement. “With our combined resources and capabilities, we have the opportunity to make a significant impact on breast cancer detection and patient outcomes around the world.”
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.